Delayed treatment with nimesulide reduces measures of oxidative stress following global ischemic brain injury in gerbils
E. Candelario-Jalil, D. Alvarez, N. Merino, O. S. Leon

TL;DR
This study demonstrates that delayed administration of nimesulide reduces oxidative stress markers and neuronal degeneration in gerbils after global ischemic brain injury, indicating its neuroprotective potential within a wide therapeutic window.
Contribution
It shows that nimesulide, a cyclooxygenase-2 inhibitor, can attenuate oxidative stress and neuronal damage after ischemia even when administered hours later.
Findings
Nimesulide reduces hippocampal oxidative stress markers.
Delayed treatment still offers neuroprotection.
Fewer degenerating neurons observed with nimesulide.
Abstract
Metabolism of arachidonic acid by cyclooxygenase is one of the primary sources of reactive oxygen species in the ischemic brain. Neuronal overexpression of cyclooxygenase-2 has recently been shown to contribute to neurodegeneration following ischemic injury. In the present study, we examined the possibility that the neuroprotective effects of the cyclooxygenase-2 inhibitor nimesulide would depend upon reduction of oxidative stress following cerebral ischemia. Gerbils were subjected to 5 min of transient global cerebral ischemia followed by 48 h of reperfusion and markers of oxidative stress were measured in hippocampus of gerbils receiving vehicle or nimesulide treatment at three different clinically relevant doses (3, 6 or 12 mg/kg). Compared with vehicle, nimesulide significantly (P<0.05) reduced hippocampal glutathione depletion and lipid peroxidation, as assessed by the levels of…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsInflammatory mediators and NSAID effects · Eicosanoids and Hypertension Pharmacology · Peroxisome Proliferator-Activated Receptors
